Literature DB >> 25614308

Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature.

Isidro Vitoria1, Elena Martín-Hernández, Luis Peña-Quintana, María Bueno, Pilar Quijada-Fraile, Jaime Dalmau, Sofia Molina-Marrero, Belén Pérez, Begoña Merinero.   

Abstract

BACKGROUND: Carnitine-acylcarnitine translocase (CACT) deficiency is a rare autosomal recessive disease in the mitochondrial transport of long-chain fatty acids. Despite early diagnosis and treatment, the disease still has a high mortality rate.
METHODS: Clinical symptoms, long-term follow-up, and biochemical and molecular results of four cases are described and compared with the reviewed literature data of 55 cases.
RESULTS: Two cases with neonatal onset, carrying in homozygosity the novel variant sequences p.Gly20Asp (c.59G>A) and p.Arg179Gly (c.536A>G), died during an intercurrent infectious process in the first year of life despite adequate dietetic treatment (frequent feeding, high-carbohydrate/low-fat diet, MCT, carnitine). The other two cases, one with infantile onset and the other diagnosed in the newborn period after a previous affected sibling, show excellent development at 4 and 16 years of age under treatment. The review shows that the most frequent presenting symptoms of CACT deficiency are hypoketotic hypoglycemia, hyperammonemia, hepatomegaly, cardiomyopathy and/or arrhythmia, and respiratory distress. The onset of symptoms is predominantly neonatal in 82% and infantile in 18%. The mortality rate is high (65%), most in the first year of life due to myocardiopathy or sudden death. Outcomes seem to correlate better with the absence of cardiac disease and with a higher long-chain fatty acid oxidation rate in cultured fibroblasts than with residual enzyme activity.
CONCLUSION: Diagnosis before the occurrence of clinical symptoms by tandem MS-MS and very early therapeutic intervention together with good dietary compliance could lead to a better prognosis, especially in milder clinical cases.

Entities:  

Year:  2015        PMID: 25614308      PMCID: PMC4375124          DOI: 10.1007/8904_2014_382

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  46 in total

1.  Bezafibrate for an inborn mitochondrial beta-oxidation defect.

Authors:  Jean-Paul Bonnefont; Jean Bastin; Anthony Behin; Fatima Djouadi
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

Review 2.  Diseases caused by defects of mitochondrial carriers: a review.

Authors:  Ferdinando Palmieri
Journal:  Biochim Biophys Acta       Date:  2008-03-25

3.  Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression.

Authors:  Vito Iacobazzi; Paolo Convertini; Vittoria Infantino; Pasquale Scarcia; Simona Todisco; Ferdinando Palmieri
Journal:  Biochem Biophys Res Commun       Date:  2009-08-06       Impact factor: 3.575

4.  Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocase.

Authors:  H Ogier de Baulny; A Slama; G Touati; D M Turnbull; M Pourfarzam; M Brivet
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

5.  Fatty Acid oxidation disorders in a chinese population in taiwan.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Mei-Chyn Chao; Li-Chu Chen; Li-Hsin Chen; Chun-Ching Chien; Hui-Chen Ho; Jeng-Hung Suen; Wuh-Liang Hwu
Journal:  JIMD Rep       Date:  2013-05-23

6.  Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts.

Authors:  S V Pande; M Brivet; A Slama; F Demaugre; C Aufrant; J M Saudubray
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency.

Authors:  Vito Iacobazzi; Federica Invernizzi; Silvia Baratta; Roser Pons; Wendy Chung; Barbara Garavaglia; Carlo Dionisi-Vici; Antonia Ribes; Rossella Parini; Maria Dolores Huertas; Susana Roldan; Graziantonio Lauria; Ferdinando Palmieri; Franco Taroni
Journal:  Hum Mutat       Date:  2004-10       Impact factor: 4.878

8.  Three novel mutations in the carnitine-acylcarnitine translocase (CACT) gene in patients with CACT deficiency and in healthy individuals.

Authors:  Takao Fukushima; Hidetoshi Kaneoka; Tetsuhiko Yasuno; Yukari Sasaguri; Tomoko Tokuyasu; Kuniko Tokoro; Toshiyuki Fukao; Takao Saito
Journal:  J Hum Genet       Date:  2013-10-03       Impact factor: 3.172

Review 9.  Carnitine-acylcarnitine translocase deficiency: case report and review of the literature.

Authors:  M E Rubio-Gozalbo; P Vos; P Ph Forget; S B Van Der Meer; R J A Wanders; H R Waterham; J A Bakker
Journal:  Acta Paediatr       Date:  2003-04       Impact factor: 2.299

10.  Carnitine-acylcarnitine carrier deficiency: identification of the molecular defect in a patient.

Authors:  M Huizing; U Wendel; W Ruitenbeek; V Iacobazzi; L IJlst; P Veenhuizen; P Savelkoul; L P van den Heuvel; J A Smeitink; R J Wanders; J M Trijbels; F Palmieri
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

View more
  8 in total

Review 1.  Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism.

Authors:  Sander M Houten; Ronald J A Wanders; Pablo Ranea-Robles
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-02-10       Impact factor: 5.187

2.  Triheptanoin: A Rescue Therapy for Cardiogenic Shock in Carnitine-acylcarnitine Translocase Deficiency.

Authors:  Sidharth Mahapatra; Amitha Ananth; Nancy Baugh; Mihaela Damian; Gregory M Enns
Journal:  JIMD Rep       Date:  2017-07-09

Review 3.  Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders.

Authors:  Deborah Marsden; Camille L Bedrosian; Jerry Vockley
Journal:  Genet Med       Date:  2021-01-25       Impact factor: 8.822

Review 4.  Carnitine-acylcarnitine translocase deficiency with c.199-10 T>G and novel c.1A>G mutation: Two case reports and brief literature review.

Authors:  Hui-Ming Yan; Hao Hu; Aisha Ahmed; Bing-Bing Feng; Jing Liu; Zheng-Jun Jia; Hua Wang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

Review 5.  Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.

Authors:  Suzan J G Knottnerus; Jeannette C Bleeker; Rob C I Wüst; Sacha Ferdinandusse; Lodewijk IJlst; Frits A Wijburg; Ronald J A Wanders; Gepke Visser; Riekelt H Houtkooper
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

6.  The use of sodium DL-3-Hydroxybutyrate in severe acute neuro-metabolic compromise in patients with inherited ketone body synthetic disorders.

Authors:  Kaustuv Bhattacharya; Walid Matar; Adviye Ayper Tolun; Beena Devanapalli; Sue Thompson; Troy Dalkeith; Kate Lichkus; Michel Tchan
Journal:  Orphanet J Rare Dis       Date:  2020-02-18       Impact factor: 4.123

7.  A novel homozygous missense SLC25A20 mutation in three CACT-deficient patients: clinical and autopsy data.

Authors:  Yasutsugu Chinen; Kumiko Yanagi; Sadao Nakamura; Noriko Nakayama; Motoko Kamiya; Mami Nakayashiro; Tadashi Kaname; Kenji Naritomi; Koichi Nakanishi
Journal:  Hum Genome Var       Date:  2020-04-16

8.  Late-Onset Carnitine-Acylcarnitine Translocase Deficiency With SLC25A20 c.199-10T>G Variation: Case Report and Pathologic Analysis of Liver Biopsy.

Authors:  Min Chen; Yao Cai; Sitao Li; Hui Xiong; Mengxian Liu; Fei Ma; Xin Xiao; Hu Hao
Journal:  Front Pediatr       Date:  2020-10-30       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.